JP2010517513A5 - - Google Patents

Download PDF

Info

Publication number
JP2010517513A5
JP2010517513A5 JP2009547285A JP2009547285A JP2010517513A5 JP 2010517513 A5 JP2010517513 A5 JP 2010517513A5 JP 2009547285 A JP2009547285 A JP 2009547285A JP 2009547285 A JP2009547285 A JP 2009547285A JP 2010517513 A5 JP2010517513 A5 JP 2010517513A5
Authority
JP
Japan
Prior art keywords
antibody
seq
human
isolated antibody
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009547285A
Other languages
English (en)
Japanese (ja)
Other versions
JP5618544B2 (ja
JP2010517513A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/000884 external-priority patent/WO2008091641A2/en
Publication of JP2010517513A publication Critical patent/JP2010517513A/ja
Publication of JP2010517513A5 publication Critical patent/JP2010517513A5/ja
Application granted granted Critical
Publication of JP5618544B2 publication Critical patent/JP5618544B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009547285A 2007-01-24 2008-01-24 癌の診断および処置のための組成物および方法 Expired - Fee Related JP5618544B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88641407P 2007-01-24 2007-01-24
US60/886,414 2007-01-24
PCT/US2008/000884 WO2008091641A2 (en) 2007-01-24 2008-01-24 Compositions and methods for diagnosing and treating cancer

Publications (3)

Publication Number Publication Date
JP2010517513A JP2010517513A (ja) 2010-05-27
JP2010517513A5 true JP2010517513A5 (enExample) 2011-03-10
JP5618544B2 JP5618544B2 (ja) 2014-11-05

Family

ID=39645070

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009547285A Expired - Fee Related JP5618544B2 (ja) 2007-01-24 2008-01-24 癌の診断および処置のための組成物および方法

Country Status (6)

Country Link
US (4) US8088617B2 (enExample)
EP (1) EP2125887A4 (enExample)
JP (1) JP5618544B2 (enExample)
AU (1) AU2008209482B2 (enExample)
CA (1) CA2676008A1 (enExample)
WO (1) WO2008091641A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906116B2 (en) * 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
ES2413087T3 (es) 2006-06-13 2013-07-15 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para el diagnóstico y tratamiento del cáncer
WO2008091641A2 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
CN102112490B (zh) 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
WO2010021729A2 (en) * 2008-08-22 2010-02-25 The Trustees Of Columbia University In The City Of New York Human notch3 based fusion proteins as decoy inhibitors of notch3 signaling
AR073717A1 (es) 2008-10-01 2010-11-24 Genentech Inc Anticuerpos anti-notch2 de murino y humano, y metodos de uso
WO2010141249A2 (en) * 2009-06-02 2010-12-09 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-notch3 antibodies
MX342250B (es) * 2009-09-30 2016-09-22 Genentech Inc Tratamiento de cánceres resistentes a antagonistas notch1, mediante el uso de antagonistas notch3.
MX2012008085A (es) 2010-01-13 2012-09-12 Oncomed Pharm Inc Agentes de union notch1 y metodos de uso de los mismos.
WO2012003472A1 (en) * 2010-07-02 2012-01-05 Aveo Pharmaceuticals, Inc. Anti-notch1 antibodies
TW201329105A (zh) * 2011-10-04 2013-07-16 Thr Trustees Of Columbia University In The City Of New York 人類notch1引誘物
US9352039B2 (en) 2012-02-09 2016-05-31 The Regents Of The University Of Michigan Method of reducing the number of EMT and MET type breast cancer stem cells
BR112015003032B1 (pt) 2012-08-13 2023-03-28 Genentech, Inc Anticorpos isolados, imunoconjugado, formulação farmacêutica e uso do anticorpo
WO2014100435A1 (en) * 2012-12-19 2014-06-26 Aveo Pharmaceuticals, Inc. Anti-notch3 antibodies
EP2970468B1 (en) 2013-03-13 2021-07-07 Novartis AG Notch2 binding molecules for treating respiratory diseases
EP3611189A1 (en) * 2013-03-14 2020-02-19 Novartis AG Antibodies against notch 3
WO2014172653A2 (en) * 2013-04-19 2014-10-23 Aveo Pharmaceuticals, Inc. Anti-notch1 antibodies
CN106488775A (zh) 2014-07-11 2017-03-08 基因泰克公司 Notch途径抑制
US11142573B2 (en) 2016-04-29 2021-10-12 Aveo Pharmaceuticals, Inc. Anti-Notch3 antibody
CN111349166B (zh) * 2018-12-20 2022-11-08 东莞市朋志生物科技有限公司 一种抗人ca72-4糖蛋白的重组抗体

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1446973A (en) * 1973-09-24 1976-08-18 Asahi Chemical Ind Method of removing nitrogen monoxide from a nitrogen mono xide-containing gas
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
IL101728A (en) 1991-05-03 2007-08-19 Univ Yale Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
IE20030749A1 (en) * 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
US20050112121A1 (en) * 1992-04-30 2005-05-26 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
DE4425115A1 (de) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
AU5752696A (en) 1995-05-18 1996-11-29 Regents Of The University Of Michigan, The Dna binding antibodies
DE69713336T2 (de) 1996-03-30 2002-12-05 Science Park Raf S.P.A., Milano Verfahren zur Herstellung von aktivierten markierten tumorspezifischen T-Zellen und deren Verwendung in der Behandlung von Tumoren
CA2256481A1 (en) 1996-05-31 1997-12-04 The National American Red Cross Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
FR2751986B1 (fr) * 1996-08-01 1998-12-31 Inst Nat Sante Rech Med Gene implique dans le cadasil, methode de diagnostic et application therapeutique
CN1524583A (zh) 1996-11-07 2004-09-01 能够表达Notch-配体的基因在制备用于免疫治疗的药物中的应用
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
WO1998057621A1 (en) 1997-06-18 1998-12-23 The Trustees Of Columbia University In The City Ofnew York Angiogenic modulation by notch signal transduction
US6379925B1 (en) 1997-06-18 2002-04-30 The Trustees Of Columbia University In The City Of New York Angiogenic modulation by notch signal transduction
US6692919B1 (en) 1997-07-23 2004-02-17 Yale University Activated forms of notch and methods based thereon
US6004528A (en) * 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
US7361336B1 (en) * 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
EP1117778A2 (en) * 1998-10-02 2001-07-25 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods and compositions for inducing differentiation and apoptosis in cells that overexpress the notch protein
US20030003572A1 (en) 1999-03-05 2003-01-02 David J. Anderson Isolation and enrichment of neural stem cells from uncultured tissue based on cell-surface marker expression
US20020010320A1 (en) 1999-04-05 2002-01-24 James W. Fett Chemeric and humanized antibodies to angiogenin
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US20030031670A1 (en) * 1999-11-08 2003-02-13 Jack R. Wands Diagnosis and treatment of malignant neoplasms
DE10031380A1 (de) 2000-06-28 2002-01-10 Merck Patent Gmbh Verfahren zur Übertragung von Alkyliden-Gruppen auf organischen Verbindungen
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US20080194022A1 (en) 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US20020151487A1 (en) 2000-08-31 2002-10-17 Loyola University Chicago Method and reagents for epithelial barrier formation and treatment of malignant and benign skin disorders by modulating the notch pathway
US6689744B2 (en) * 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses
CN1395617A (zh) 2000-10-02 2003-02-05 韩国生命工学研究院 抗乙肝病毒表面抗原s的人源化抗体及其制备方法
AU2002307494A1 (en) 2001-04-24 2002-11-05 Bayer Corporation Human timp-1 antibodies
US7356224B2 (en) * 2001-07-03 2008-04-08 Brown University Research Foundation Method and apparatus for detecting multiple optical wave lengths
WO2003042246A2 (en) * 2001-11-14 2003-05-22 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer
AU2002364537A1 (en) 2001-12-07 2003-06-23 Regents Of The University Of Michigan Prospective identification and characterization of breast cancer stem cells
GB0201674D0 (en) 2002-01-25 2002-03-13 Lorantis Ltd Medical treatment
EP2365004B1 (en) 2002-06-21 2016-01-06 Johns Hopkins University School of Medicine Membrane associated tumor endothelium markers
EP1578367A4 (en) * 2002-11-01 2012-05-02 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
EP1567186A2 (en) 2002-12-06 2005-08-31 Singapore General Hospital Pte. Ltd. Nogo, caspr, f3 and nb-3 useful in the treatment of injury and disease to the central nervous system
JP2007525167A (ja) 2003-04-01 2007-09-06 ジェンザイム・コーポレーション 乳房内皮細胞発現パターン
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
GB0321805D0 (en) 2003-09-18 2003-10-15 Univ Wales Medicine Human tumour growth patterns
JP2007512348A (ja) 2003-11-26 2007-05-17 ヘルス リサーチ インコーポレイテッド 形質細胞の治療のためのノッチ経路干渉剤の使用
WO2005074633A2 (en) * 2004-02-03 2005-08-18 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
WO2005090981A2 (en) * 2004-03-24 2005-09-29 Technion Research & Development Foundation Ltd. Electrode
WO2005111072A2 (en) * 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
US20070077245A1 (en) 2004-08-04 2007-04-05 The Brigham And Women's Hospital, Inc. NOTCH mutations leading to increased receptor signaling
GB0421838D0 (en) * 2004-09-30 2004-11-03 Congenia S R L Cancer markers
WO2006053063A2 (en) 2004-11-05 2006-05-18 The Regents Of The University Of California Notch-1 assay to detect neurodegenerative diseases
NZ555216A (en) * 2004-11-10 2010-05-28 Hubrecht Lab Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation
WO2006051405A2 (en) * 2004-11-12 2006-05-18 Cambridge University Technical Services Ltd. Methods and means related to cancer stem cells
CA2604844A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics, Inc. Cancer-related genes
US20090305310A1 (en) 2005-11-22 2009-12-10 University Of Vermont And State Agricultural College Methods for Determining Notch Signaling and Uses Thereof
WO2007075914A2 (en) 2005-12-22 2007-07-05 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies against orthopoxviruses
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
US20080241150A1 (en) 2006-05-15 2008-10-02 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human NOTCH1 and 2 and isolated LNR domains from human NOTCH1
ES2413087T3 (es) 2006-06-13 2013-07-15 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para el diagnóstico y tratamiento del cáncer
DK2066694T3 (en) * 2006-09-29 2016-02-08 Oncomed Pharm Inc Compositions and Methods for Diagnosing and Treating Cancer
US7700113B2 (en) * 2006-10-19 2010-04-20 Maine Medical Research Institute, A Division Of Maine Medical Center Inhibiting breast cancer cell growth by administering an intracellular domain of NOTCH2
RU2461569C2 (ru) 2006-10-19 2012-09-20 Дженентек, Инк. Агонистические антитела против notch3 и их применение для лечения notch3-ассоциированных заболеваний
PE20080891A1 (es) 2006-10-19 2008-08-25 Genentech Inc Anticuerpos anti-notch3 y composiciones que los comprenden
US20100068688A1 (en) 2006-11-06 2010-03-18 Howard Shapiro Management of teaching processes for individualized instruction in a multistudent environment
AU2007333805B2 (en) * 2006-12-18 2013-07-25 Genentech, Inc. Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases
WO2008091641A2 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US20090208491A1 (en) 2007-02-14 2009-08-20 Austin Gurney Compositions and Methods for Diagnosing and Treating Cancer
US20100099090A1 (en) 2007-03-05 2010-04-22 Bristol-Mayers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
JP2010520280A (ja) 2007-03-05 2010-06-10 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システム NotchまたはNumb特異的免疫療法との相乗効果を有する、癌細胞の再生のネガティブな遺伝的制御
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
PE20090943A1 (es) 2007-07-16 2009-08-05 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados
US9127085B2 (en) 2007-08-23 2015-09-08 The Trustees Of Columbia University In The City Of New York Compositions of humanized notch fusion proteins and methods of treatment
EP2195451A4 (en) 2007-08-28 2011-01-19 Merck Sharp & Dohme EXPRESSION PROFILES OF BIOMARKERGENIC IN NOTCH-MEDIATED CANCER DISEASES
US8377886B2 (en) 2007-09-14 2013-02-19 Albert Einstein College Of Medicine Of Yeshiva University Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
US7807630B2 (en) 2007-09-14 2010-10-05 Vanderbilt University Targeting of Notch3 receptor function for cancer therapy
US20120082659A1 (en) 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
US8119366B2 (en) 2007-10-05 2012-02-21 Trojan Technologies, Ltd. Antennapedia-dominant negative mastermind-like construct
JP2011516520A (ja) 2008-04-07 2011-05-26 アブリンクス エン.ヴェー. Notch経路に指向性を有するアミノ酸配列及びその使用
CN102112490B (zh) 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
AR073717A1 (es) 2008-10-01 2010-11-24 Genentech Inc Anticuerpos anti-notch2 de murino y humano, y metodos de uso
WO2010105207A1 (en) 2009-03-13 2010-09-16 The Regents Of The University Of California Prebiotic oligosaccharides
MX342250B (es) 2009-09-30 2016-09-22 Genentech Inc Tratamiento de cánceres resistentes a antagonistas notch1, mediante el uso de antagonistas notch3.
DE102009047243A1 (de) 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien
MX2012008085A (es) 2010-01-13 2012-09-12 Oncomed Pharm Inc Agentes de union notch1 y metodos de uso de los mismos.
CA2789446A1 (en) 2010-02-12 2011-08-18 Oncomed Pharmaceuticals, Inc. Methods for identifying and isolating cells expressing a polypeptide
JP5450221B2 (ja) 2010-04-14 2014-03-26 株式会社神戸製鋼所 高電流密度ガスシールドアーク溶接方法
HRP20190047T1 (hr) 2010-05-04 2019-02-22 Five Prime Therapeutics, Inc. Protutijela koja se vežu na csf1r
WO2012003472A1 (en) 2010-07-02 2012-01-05 Aveo Pharmaceuticals, Inc. Anti-notch1 antibodies
AU2011342799B2 (en) 2010-12-15 2016-06-09 Wyeth Llc Anti-Notch1 antibodies
TR201909840T4 (tr) 2011-03-11 2019-07-22 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antikorları ve kullanımları.
EP2780354A4 (en) 2011-11-16 2015-06-24 Oncomed Pharm Inc HUMAN NOTCH RECEPTOR MUTATIONS AND THEIR USE
US20130323266A1 (en) 2012-05-16 2013-12-05 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with notch2/3 antibodies
DK2892524T3 (da) 2012-09-04 2021-01-25 Eleison Pharmaceuticals LLC Forebyggelse af pulmonalt kræfttilbagefald med lipid-komplekseret cisplatin
EP2897643A4 (en) 2012-09-21 2016-04-20 Oncomed Pharm Inc METHOD FOR THE TREATMENT OF MOLECULAR BLOOD DISEASES WITH NOTCH1 ANTIBODIES
CA2890571A1 (en) 2012-11-07 2014-05-15 Kenneth G. Geles Anti-notch3 antibodies and antibody-drug conjugates
WO2014151606A2 (en) 2013-03-15 2014-09-25 Oncomed Pharmaceuticals, Inc. Methods of treating pancreatic cancer
AU2015227247A1 (en) 2014-03-07 2016-09-15 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with Notch 1 antibodies
US20170023576A1 (en) 2014-04-04 2017-01-26 Oncomed Pharmaceuticals, Inc. Notch3 antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP2010517513A5 (enExample)
JP2020501531A5 (enExample)
JP2023509196A5 (enExample)
RU2019116624A (ru) Новые анти_cd137 антитела и их применение
JP2019513018A5 (enExample)
JP2019533719A5 (enExample)
JP2010532169A5 (enExample)
JP2017519759A5 (enExample)
JP2015500207A5 (enExample)
JP2015509947A5 (enExample)
JP2014531201A5 (enExample)
JP2010534478A5 (enExample)
ME02371B (me) Sastojci i postupci za dijagnstikovanje i tretman raka
RU2014113304A (ru) Анти-cd40-антитела, применение и методы
JP2009541492A5 (enExample)
JP2017529838A5 (enExample)
JP2018506961A5 (enExample)
JP2022545741A5 (enExample)
JP7350740B2 (ja) Ildr2アンタゴニストおよびその組み合わせ
JP2016538832A5 (enExample)
JP2024504390A5 (enExample)
JP2024016024A5 (enExample)
JP2021520201A5 (enExample)
JP2021512159A5 (enExample)
JP2013521252A5 (enExample)